Joyce O’Shaughnessy, MD - Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple-Negative Breast Cancer - a podcast by PVI, PeerView Institute for Medical Education
from 2021-07-16T18:00
Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education